MGNX vs. INVA, LQDA, CNTA, ABVX, ZNTL, SAVA, IMNM, OPK, TYRA, and BLTE
Should you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Innoviva (INVA), Liquidia (LQDA), Centessa Pharmaceuticals (CNTA), ABIVAX Société Anonyme (ABVX), Zentalis Pharmaceuticals (ZNTL), Cassava Sciences (SAVA), Immunome (IMNM), OPKO Health (OPK), Tyra Biosciences (TYRA), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical preparations" industry.
Innoviva (NASDAQ:INVA) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, community ranking, profitability and media sentiment.
Innoviva has a net margin of 57.89% compared to Innoviva's net margin of -15.42%. MacroGenics' return on equity of 30.37% beat Innoviva's return on equity.
Innoviva has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.
99.1% of Innoviva shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 1.4% of Innoviva shares are owned by insiders. Comparatively, 11.3% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Innoviva has higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
In the previous week, MacroGenics had 5 more articles in the media than Innoviva. MarketBeat recorded 9 mentions for MacroGenics and 4 mentions for Innoviva. MacroGenics' average media sentiment score of 1.03 beat Innoviva's score of 0.76 indicating that Innoviva is being referred to more favorably in the media.
MacroGenics received 123 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 63.33% of users gave MacroGenics an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
MacroGenics has a consensus target price of $18.00, indicating a potential upside of 21.29%. Given Innoviva's higher possible upside, analysts clearly believe MacroGenics is more favorable than Innoviva.
Summary
Innoviva beats MacroGenics on 9 of the 17 factors compared between the two stocks.
Get MacroGenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MacroGenics Competitors List
Related Companies and Tools
